These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 33589319)

  • 41. Microelimination could be a big deal for HCV and HIV services.
    The Lancet Hiv
    Lancet HIV; 2018 Nov; 5(11):e605. PubMed ID: 30507440
    [No Abstract]   [Full Text] [Related]  

  • 42. A model of the economic benefits of global hepatitis C elimination: an investment case.
    Scott N; Kuschel C; Pedrana A; Schroeder S; Howell J; Thompson A; Wilson DP; Hellard M
    Lancet Gastroenterol Hepatol; 2020 Oct; 5(10):940-947. PubMed ID: 32730785
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Global burden of hepatitis C: considerations for healthcare providers in the United States.
    Averhoff FM; Glass N; Holtzman D
    Clin Infect Dis; 2012 Jul; 55 Suppl 1():S10-5. PubMed ID: 22715208
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Reaching hepatitis C virus elimination targets requires health system interventions to enhance the care cascade.
    Scott N; Doyle JS; Wilson DP; Wade A; Howell J; Pedrana A; Thompson A; Hellard ME
    Int J Drug Policy; 2017 Sep; 47():107-116. PubMed ID: 28797497
    [TBL] [Abstract][Full Text] [Related]  

  • 45. HCV elimination - lessons learned from a small Eurasian country, Georgia.
    Nasrullah M; Sergeenko D; Gamkrelidze A; Averhoff F
    Nat Rev Gastroenterol Hepatol; 2017 Jul; 14(8):447-448. PubMed ID: 28743936
    [No Abstract]   [Full Text] [Related]  

  • 46. Hepatitis C: only a step away from elimination?
    Lancet; 2015 Mar; 385(9973):1045. PubMed ID: 25797543
    [No Abstract]   [Full Text] [Related]  

  • 47. Identifying the lower age limit for hepatitis C screening in large elimination programmes in highly endemic areas.
    Hamid S; Abid A; Dore GJ
    Lancet Gastroenterol Hepatol; 2021 Feb; 6(2):89-90. PubMed ID: 33444535
    [No Abstract]   [Full Text] [Related]  

  • 48. Eliminating hepatitis C: The importance of frequent testing of people who inject drugs in high-prevalence settings.
    Scott N; Sacks-Davis R; Pedrana A; Doyle J; Thompson A; Hellard M
    J Viral Hepat; 2018 Dec; 25(12):1472-1480. PubMed ID: 30047625
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Direct-Acting Antiviral Therapy for Hepatitis C Virus Infection: Fulfilling the Potential on the Road to Elimination.
    Naggie S; Wyles D
    J Infect Dis; 2020 Nov; 222(Suppl 9):S741-S744. PubMed ID: 33245351
    [No Abstract]   [Full Text] [Related]  

  • 50. Micro-elimination - A path to global elimination of hepatitis C.
    Lazarus JV; Wiktor S; Colombo M; Thursz M;
    J Hepatol; 2017 Oct; 67(4):665-666. PubMed ID: 28760329
    [No Abstract]   [Full Text] [Related]  

  • 51. Neglected Tropical Diseases, Neglected Communities, and Conflict: How Do We Leave No One Behind?
    Jacobson J; Bush S
    Trends Parasitol; 2018 Mar; 34(3):175-177. PubMed ID: 29162404
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Hepatitis C: Is eradication possible?
    Lombardi A; Mondelli MU;
    Liver Int; 2019 Mar; 39(3):416-426. PubMed ID: 30472772
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Eliminating HCV: a marathon, not a sprint.
    The Lancet Gastroenterology Hepatology
    Lancet Gastroenterol Hepatol; 2020 Jun; 5(6):515. PubMed ID: 32416859
    [No Abstract]   [Full Text] [Related]  

  • 54. Linkage and retention in HCV care for HIV-infected populations: early data from the DAA era.
    Sacks-Davis R; Doyle JS; Rauch A; Beguelin C; Pedrana AE; Matthews GV; Prins M; van der Valk M; Klein MB; Saeed S; Lacombe K; Chkhartishvili N; Altice FL; Hellard ME
    J Int AIDS Soc; 2018 Apr; 21 Suppl 2(Suppl Suppl 2):e25051. PubMed ID: 29633559
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The Micro-Elimination Approach to Eliminating Hepatitis C: Strategic and Operational Considerations.
    Lazarus JV; Safreed-Harmon K; Thursz MR; Dillon JF; El-Sayed MH; Elsharkawy AM; Hatzakis A; Jadoul M; Prestileo T; Razavi H; Rockstroh JK; Wiktor SZ; Colombo M
    Semin Liver Dis; 2018 Aug; 38(3):181-192. PubMed ID: 29986353
    [TBL] [Abstract][Full Text] [Related]  

  • 56. What is required for achieving hepatitis C virus elimination in Singapore? A modeling study.
    Chaillon A; Thurairajah PH; Hsiang JC; Martin NK
    J Gastroenterol Hepatol; 2021 Apr; 36(4):1110-1117. PubMed ID: 32777859
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Guidelines Have a Key Role in Driving HCV Elimination by Advocating for Simple HCV Care Pathways.
    Mangia A; Albanese AP; Bourliére M; Craxi A; Dieterich D; Solomon S; Vanstraelen K; Hernandez C; Turnes J
    Adv Ther; 2021 Mar; 38(3):1397-1403. PubMed ID: 33590446
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The Second Biggest Infectious Disease Killer in the U.S.: Hepatitis C Virus Infection and Steps Towards its Elimination in Rhode Island and Beyond.
    Taylor LE
    R I Med J (2013); 2020 Jun; 103(5):19-21. PubMed ID: 32481774
    [No Abstract]   [Full Text] [Related]  

  • 59. Preface.
    Abela-Ridder B
    Vaccine; 2019 Oct; 37 Suppl 1():A2. PubMed ID: 31564304
    [No Abstract]   [Full Text] [Related]  

  • 60. Cost-Effectiveness of Testing and Treatment for Hepatitis B Virus and Hepatitis C Virus Infections: An Analysis by Scenarios, Regions, and Income.
    Tordrup D; Hutin Y; Stenberg K; Lauer JA; Hutton DW; Toy M; Scott N; Chhatwal J; Ball A
    Value Health; 2020 Dec; 23(12):1552-1560. PubMed ID: 33248510
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.